Derek Chalmers
President & CEO
Cara Therapeutics, Inc.
Shelton, Connecticut
Ho Cho
Vice President Molecular Technology & Process Development
Ambrx, Inc.
La Jolla, California
Graham Cooks
Department of Chemistry
Purdue University
West Lafayette, Indiana
Phil Dawson
Scripps Institute
San Diego, California
David D’Alessio
Director, Division of Endocrinology, Diabetes & Metabolism
University of Cincinnati
Cincinnati, Ohio
Patricia Ducy
Assistant Professor of Pathology
Columbia University
New York, New York
Bio: Jonathan Ellman's laboratory is focused on the development and of new synthesis methods, in particular asymmetric amine synthesis and C-H activation chemistry, and the development of chemical tools to study enzymes. He is a fellow of the American Association for the Advancement of Science, and has received a number of awards, including the Tetrahedron Young Investigator Award for Bioorganic and Medicinal Chemistry (2006), the Society of Biomolecular Screening Achievement Award (2003), and an ACS Cope Scholar Award (2000).
 |
Joseph Garlich
President & Chief Scientist
Semafore Pharmaceuticals, Inc.
Indianapolis, Indiana
|
Bio: Dr. Garlich has over 23 years experience as a scientist, inventor and director of drug discovery and development. He co-founded Semafore Pharmaceuticals (then called ComChem Technologies) in 2000 and has since directed all of the company’s scientific research activities, including scientific strategy, drug discovery and preclinical drug development efforts. Previously, Dr. Garlich worked for 11 years in the pharmaceutical division of Dow Chemical, where he invented and developed multiple drug candidates. Dr. Garlich has served as the principal investigator for six peer-reviewed grants awarded to Semafore totaling over $4.5 million and is an inventor on 24 US patents. He received a Ph.D. in Organic Chemistry at the University of Missouri.
W. Geho
SDG, Inc.
Cleveland, Ohio
 |
Sam Gellman
Ralph F. Hirschmann Professor of Chemistry
University of Wisconsin - Madison
Madison, Wisconsin
www.chem.wisc.edu/!gellman
|
Bio: Sam Gellman is the Ralph F. Hirschmann Professor of Chemistry at the University of Wisconsin - Madison. His research interests include the development of artificial oligomers ("foldamers") with protein-like structures and functions. Much of this work has focused on b-amino acid oligomers ("b-peptides") and oligomers that contain both a and b residues ("a/b-peptides"). Gellman's group is active also in more conventional areas of protein design, including the study b-sheet secondary structure and the analysis of protein conformational stability via backbone thioester exchange
Carrie Haskell-Luevano
Joint Assistant Professor
University of Florida
Gainesville, Florida
Bio: Professor Victor J. Hruby is Regents Professor in the Department of Chemistry at the University of Arizona. Professor Hruby’s research has been primarily in the chemistry, conformation-biological activity relationships, and molecular mechanisms of information transduction and of molecular diseases associated with peptide hormones and neurotransmitters and their receptors. Professor Hruby and his colleagues and students have made a number of important contributions to design, synthesis, and conformation-bioactivity relationships of novel constrained peptides and peptide mimetics of peptide hormone and neurotransmitter agonists, antagonists, partial agonists, and inverse agonists, several of which are used worldwide for biological and biomedical applications.
Amy Keating
Irwin and Helen Sizer Career Development Professor
Massachusetts Institute of Technology
Boston, Massachusetts
D. Mitchell
University of California
San Diego, California
Tom Muir
Richard E. Salomon Family Professor
Rockefeller University
New York, New York
Fred Naider
Distinguished Professor of Chemistry and Biochemistry
Leonard and Esther Kurtz Term Professor, CSI
College of Staten Island (CUNY)
Staten Island, New York
Milos Novotny
Distinguished Professor & Lilly Chair in Chemistry
Indiana University
Bloomington, Indiana
 |
Robin Offord
Founding President and Executive Director
Mintaka Foundation for Medical Research
Geneva, Switzerland
|
 |
Roger Perlmutter
Executive Vice President, Research and Development
Amgen, Inc.
Thousand Oaks, California
Opening Lecture: Monday, June 8th
|
Bio: Dr. Perlmutter is Executive Vice President for Research and Development at Amgen, Inc., the world’s largest biotechnology company. A graduate of Reed College (Portland, Oregon), Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University (St. Louis) in 1979. Thereafter he pursued clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco. From 1981 to 1984 he was a Lecturer in the Division of Biology at the California Institute of Technology. He joined the Departments of Medicine and Biochemistry and the Howard Hughes Medical Institute at the University of Washington (Seattle) in 1984, and in 1989 became Professor and Chairman of the Department of Immunology there. During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. In 1997 he left the University of Washington to join Merck and Co., where, as Executive Vice President, Worldwide Basic and Preclinical Research, he helped to craft strategies that led to the introduction of new therapies for serious infections and for diabetes, as well as vaccines to prevent cervical cancer and shingles. He left Merck in 2001 to lead the worldwide research and development efforts at Amgen, Inc. Under his direction, Amgen has successfully re-focused its discovery efforts on the amelioration of grievous illness, increasing its product portfolio by five-fold. Dr. Perlmutter is also a director of Stem Cells, Inc., a Trustee of Reed College, and Chairman of the Board of Directors of the Institute for Systems Biology, a not-for-profit research institute based in Seattle, Washington. He was previously President of the American Association of Immunologists, and is a Fellow of the American Academy of Arts and Sciences
Antonello Pessi
Director
Merck Peptide Research
Pomezia, Italy
 |
William Ringo
Executive Vice President, Strategy and Business Development
Pfizer Pharmaceuticals
New York City, New York
Opening Lecture: Wednesday, June 10th
|
Bio: Bill Ringo joined Pfizer’s Executive Leadership Team on April 1, 2008 as Senior Vice President of Strategy and Business Development. Prior to joining Pfizer, Bill was CEO in Residence at Warburg Pincus and Executive in Residence at Sofinnova Ventures. From July 2004 to April 2006, he served as the President, Chief Executive Officer and a director of Abgenix, Inc., at which time Abgenix was acquired by Amgen, Inc. Starting in 2002, Bill was a member the Board of Directors at Intermune, a biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology, and from 2003-2008 served as Chairman of Intermune’s Board of Directors. From 1973 until 2001, Bill served in a variety of senior roles at Eli Lilly and Company, such as President of Oncology and Critical Care Products, President of Internal Medicine Products, and President of the Infectious Disease Business Unit, as well as senior positions in sales, marketing and business planning. Bill holds a B.S. in Business Administration and an M.B.A. from the University of Dayton.
Gebhardt Schertler
Medical Research Council laboratory of Molecular Biology
Cambridge, United Kingdom
Tomi Sawyer
Chief Scientific Officer
Aileron Therapeutics
Cambridge, Massachusetts
Randy Seeley
Professor of Psychiatry
University of Cincinnati
Cincinnati, Ohio
 |
Peter Schultz
Scripps Family Chair Professor
The Scripps research Institute Scripps Institute
San Diego, California
http://schultz.scripps.edu
|
Bio: Peter G. Schultz graduated (summa cum laude) from Caltech in 1979 and continued there for his doctoral degree (in 1984) with Professor Peter Dervan. He then spent a year at the Massachusetts Institute of Technology with Professor Christopher Walsh before moving to the University of California, Berkeley, and the Howard Hughes Medical Institute. He is currently the Scripps Professor of Chemistry at The Scripps Research Institute and Director of the Genomics Institute of the Novartis Research Foundation. Schultz has made a number of major contributions to science including: (1) the discovery of catalytic antibodies, and their use to study fundamental mechanisms of biological catalysis and the evolution of binding and catalytic function; (2) the development of technology that for the first time enables the systematic expansion of the genetic codes of living organisms to include unnatural amino acids beyond the common twenty; and (3) the development and application of combinatorial methods in chemistry and biology including the first generation of combinatorial materials libraries and the isolation of molecules that control stem cell proliferation and fate. Schultz has received numerous awards including the Alan T. Waterman Award, NSF (1988), the ACS Award in Pure Chemistry (1990), the U.C. Berkeley College of Chemistry Teaching Award (1992), the Wolf Prize in Chemistry (1994), the Paul Erhlich and Ludwig Darmstaedter Award (2002), and the ACS Arthur C. Cope Award (2006). Professor Schultz is a member of the National Academy of Sciences, USA (1993) and the Institute of Medicine of the National Academy of Sciences (1998). He is active on many editorial and scientific advisory boards and is a founder of Affymax Research Institute, Symyx Technologies, Syrrx, Kalypsys, Phenomix, Ilypsa, Ambrx and Wildcat Discovery Technolgies.
 |
Steven Smith
Professor and Director of Structural Biology
Department of Biochemistry and Cell biology
Stony Brook University
Stony Brook, New York
http://sos.bio.sunysb.edu (lab homepage)
http://csb.sunysb.edu (structural biology homepage
|
Bio: The overall goal of our research has been to understand in structural and chemical terms how membrane proteins function. Current work focuses on the molecular mechanisms of signal transduction by G protein-coupled receptors and receptor tyrosine kinases, and the mechanism of selectivity and gating by ion channel proteins. One aspect of the research has been the development of biophysical methods for structural studies, with the dominant approaches being magic spinning NMR and vibrational spectroscopy.
Bio: In 2007, Dr. Mark Staples founded Cusp PharmaTech Consulting LLC in Cambridge, MA. During the previous decade, his titles were at the Director and Vice President levels at several early stage companies. Highlights of his product development activities include pharmaceutical development and commercialization of proteins (Biogen: Avonex®) and peptides (Biogen: Angiomax®; Praecis: PlenaxisTM) and project management of the technical (Chemistry Manufacturing and Controls) section of regulatory submissions. He has served as Chair of the BIOTEC Section of American Association of Pharmaceutical Scientists, and was President of the New England Chapter of the Parenteral Drug Association.
He received his Ph.D. at the University of Kansas (1979) and was a Postdoctoral Fellow at Harvard Medical SchoolIn 2007, Dr. Mark Staples founded Cusp PharmaTech Consulting LLC in Cambridge, MA. During the previous decade, his titles were at the Director and Vice President levels at several early stage companies. Highlights of his product development activities include pharmaceutical development and commercialization of proteins (Biogen: Avonex®) and peptides (Biogen: Angiomax®; Praecis: PlenaxisTM) and project management of the technical (Chemistry Manufacturing and Controls) section of regulatory submissions.
He has served as Chair of the BIOTEC Section of American Association of Pharmaceutical Scientists, and was President of the New England Chapter of the Parenteral Drug Association.
He received his Ph.D. at the University of Kansas (1979) and was a Postdoctoral Fellow at Harvard Medical School.
Reto Stocklin
Chief Scientific Officer
Atheris Laboratories
Geneva, Switzerland
 |
Roger Sunahara
Associate Professor
Department of Pharmacology
University of Michigan Medical School
Ann Arbor, Michigan
Sitemaker.umich.edu/sunahara
|
Bio: Our laboratory is primarily interested in the elucidation of the molecular mechanism by which hormones activate G protein-couple receptions (GPCRs). We utilize biochemical and biophysical approaches to delineate how hormone binding to these cell surface receptors leads to nucleotide exchange and activation of G proteins.
James Tam
Professor
Scripps Institute
Palm Beach, Florida
Matthias Tschop
Professor of Psychiatry
Obesity Research Center
University of Cincinnati – Genome Research Institute
Cincinnati, Ohio
Andrew Young
Amylin Parmaceuticals, Inc.
San Diego, California
Michael Nieuwenhze
Associate Professor
Indiana University
Bloomington, Indiana
John Vederas
Professor of Chemistry
University of Alberta
Edmonton, Alberta, Canada
 |
Gregory Verdine
Erving Professor of Chemistry
Harvard University
Director, Harvard & Dana-Farber Program in Cancer Chemical Biology
Cambridge, Massachusetts
http://verdinelab.harvard.edu
|
 |
Andrew Vick
Scientific Director
BioPharma Services
Millipore Bioscience Division
St. Louis, Missouri
http://www.millipore.com
|
Bio: Andrew Vick, Ph.D. is currently the Scientific Director of BioPharma Services at Millipore. Dr. Vick received his B.S. in Zoology and his Ph.D. in Pharmaceutical Chemistry (1998) from Ohio State University. In 1999, Dr. Vick joined the preclinical development group at Biogen where he developed toxicologic, PK, and clinical strategies to support lead programs for both biologic and small molecule candidates. In 2000, Dr. Vick joined Eli Lilly where he led ADME Teams that included a diversity of bioproduct types across all stages of therapeutic development. In 2007, Dr. Vick joined Millipore where he provides strategic, scientific, and technical leadership for BioPharma business, including support for discovery research, regulatory-compliant studies, and clinical diagnostics. His areas of research interest include the preclinical pharmacologic, toxicologic, and PK evalutaion of the therapeutic bioproducts being considered for clinical development. Specifically, Dr. Vick enjoys leveraging PK/PD tools to advance bioproduct delivery strategies (molecular-based conjugations for time-action extension, pulmonary, oral, and deport formulations).
John Wade
Laboratory Head
University of Melbourne
Parkville, Victoria, Australia
Andrew Young
Amylin Pharmaceuticals, Inc.
San Diego, CA
